Physician profile
Aman Shah
NPI 1770845851
$235,991.43
in general payments reported to CMS, 2019-2025
24 companies · $85K in 2025
The $85K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,109 · 2020: $1,110 · 2021: $24K · 2022: $23K · 2023: $37K · 2024: $64K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $70K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Honoraria: $26K · Travel and Lodging: $25K · Food and Beverage: $8,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $69,942.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,952.50 |
| Honoraria | $25,600.00 |
| Travel and Lodging | $25,121.25 |
| Food and Beverage | $8,255.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $151,916.37 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Gallant |
| Alnylam Pharmaceuticals INC. | $34,035.72 | 2020-2025 | Amvuttra, Onpattro |
| Scpharmaceuticals INC. | $28,447.38 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $10,562.95 | 2021-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $7,365.38 | 2020-2025 | Farxiga, Lokelma, Wainua |
| Novartis Pharmaceuticals Corporation | $1,063.10 | 2020-2023 | |
| Kestra Medical Technology Services, INC. | $273.38 | 2022-2023 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $252.80 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $232.95 | 2023-2025 | Uptravi, Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $231.62 | 2023-2025 | Lifevest |
| Abiomed | $222.29 | 2025 | |
| Akcea Therapeutics, INC. | $197.63 | 2020-2021 | |
| Endotronix, INC. | $162.51 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| E.R. Squibb & Sons, L.L.C. | $153.83 | 2022-2023 | Camzyos |
| Cvrx, INC. | $150.00 | 2025 | Barostim Neo System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $149.97 | 2024 | Corevalve Evolut R |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.78 | 2021-2023 | Jardiance |
| Vifor Pharma, INC. | $136.93 | 2020-2023 | Veltassa |
| Bridgebio Pharma, INC. | $120.18 | 2025 | Attruby |
| Pfizer INC. | $68.40 | 2020-2022 | |
| Daxor Corporation | $33.91 | 2022 | |
| Bioventrix, INC. | $23.55 | 2025 | |
| Amgen INC. | $22.43 | 2019 | |
| Daiichi Sankyo INC. | $20.37 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.